T estosterone, the most important androgen produced by the testes, plays an integral role in male health. 1, 2 Hypogonadism or a low circulating level of testosterone is associated with sexual dysfunction, and lower testosterone levels correlate with greater severity of erectile dysfunction (ED). 3 Testosterone levels decline with age, but only 6-12% of men have been described as developing hypogonadism as they grow older. 4, 5, 6 Many patients with hypogonadism can be treated in primary care, but where a pituitary or hypothalamic disorder is suspected, the advice of an endocrinologist should always be sought. Furthermore, the advice of an endocrinologist is necessary where there is doubt about the cause and appropriate management of the hypogonadism.
HYPOGONADISM AND HOW TO SCREEN FOR IT
Androgen deficiency in the adult male becomes more common with increasing age, but its management remains controversial. As well as sexual dysfunction, androgen deficiency is associated with osteoporosis, dyslipidaemia, type 2 diabetes, metabolic syndrome and depression. [7] [8] [9] [10] Far from being a benign consequence of ageing, hypogonadism has important and unwanted metabolic consequences, and is a significant cause of increased cardiovascular risk. 11, 12 Androgens act at several sites in the sexual response system including the central nervous system, peripheral nitrergic nerves and corpora cavernosa. Androgen deficiency may affect sexual interest, erections and responsiveness to phosphodiesterase 5 inhibitors (PDE5I). 13 Diagnosis of androgen deficiency in men is based upon the identification of its non-specific features through clinical assessment and blood testing. As there is a circadian variation in testosterone release, with peak levels in the early morning, samples for testosterone assay should be taken between 8am and 11am.
The assay should be repeated after two weeks if the circulating testosterone level is low, as testosterone is also released in a pulsatile manner and the result of a single assay may be misleading.
14 If the testosterone level is low or borderline on the first measurement, it is appropriate to add sex hormone binding globulin (SHBG) and serum albumin to enable estimation of the circulating free testosterone with the algorithm based on the Vermeulen equation (available at http://www.issam. ch/freetesto.htm). 15, 16 Free testosterone is a more reliable measure of androgen status.
It is also important to check luteinising hormone (LH), follicle-stimulating hormone (FSH) and prolactin to differentiate secondary from primary hypogonadism. Discussion with, or referral to, a specialist endocrinology clinic should be considered if the results are abnormal.
There is significant variation in laboratory reference ranges, but in general, men with a total serum testosterone that is consistently less than 11nmol/L or estimated circulating free testosterone <225pmol/L might benefit from a trial of testosterone replacement therapy for ED and should be managed in accordance with current guidelines. 2, 15 PSA should be measured before commencing testosterone and at regular intervals during testosterone therapy, as should the full blood count.
HYPERPROLACTINAEMIA
Hyperprolactinaemia is associated with ED, loss of sexual interest and anorgasmia. It is frequently accompanied by androgen deficiency, because high prolactin levels suppress LH production and, consequently, cause hypogonadism. Hyperprolactinaemia should be excluded by blood testing in all men with reduced sexual interest. Moderate elevation of prolactin levels (<1000mU/L) is unlikely to cause ED. 17 Hyperprolactinaemia can have many causes:
• medical and physical stress • drugs (notably neuroleptics and anti-emetics) • prolactin-secreting pituitary tumour (identification of these cases is very important) • chronic renal failure.
A misdiagnosis of hyperprolactinaemia can result from the presence of macroprolactin or 'big-big' prolactin. This is a heterogenous complex of prolactin and immunoglobulin, and is the cause of apparent hyperprolactinaemia in around 20% of cases. 18, 19 Macroprolactin is measured by all commercial immunoassays, to a greater or lesser extent, and its presence should be considered in all cases of mild to moderate hyperprolactinaemia. Macroprolactinaemia is diagnosed by re-assaying after precipitation with polyethylene glycol. Most clinical laboratories have protocols in place to check for this when prolactin levels are above the method-dependent cut-off (approximately 700-1000mU/L).
Patients with persistent and unexplained hyperprolactinaemia should be referred to an endocrinologist.
TREATMENT OF HYPOGONADISM
Hypogonadal men given testosterone replacement may experience:
• a general improvement in sexual function • improved erection • restored or enhanced responsiveness to PDE5I. 20, 21 There is accumulating evidence that administration of testosterone to hypogonadal males with underlying elevated cardiovascular risk can reduce mortality.
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KEY POINTS
• As there is a circadian variation in testosterone release, with peak levels in the early morning, samples for testosterone assay should be taken between 8am and 11am
• The assay should be repeated after two weeks if the circulating testosterone level is low, as testosterone is also released in a pulsatile manner and the result of a single assay may be misleading
• If the testosterone level is low or borderline on the first measurement, sex hormone binding globulin (SHBG) and serum albumin should be added to enable estimation of the circulating free testosterone
• It is important to check luteinising hormone (LH), follicle-stimulating hormone (FSH) and prolactin to differentiate secondary from primary hypogonadism
• Men with a total serum testosterone that is consistently less than 11nmol/L or estimated circulating free testosterone <225pmol/L might benefit from a trial of testosterone replacement therapy for ED
• PSA should be measured before commencing testosterone and at regular intervals during testosterone therapy www.trendsinmenshealth.com
TRENDS IN UROLOGY & MEN'S HEALTH MARCH/APRIL 2017
The cause of hypogonadism should always be sought before treatment with testosterone is initiated, but this does not mean that treatment for ED should be deferred.
A range of well-tolerated testosterone formulations is available including:
• transdermal gel (Testim, Testogel, Tostran) • long-acting injection (every 10-12 weeks) (Nebido) • traditional depot injection (three weekly) (Sustanon 250) • buccal (twice daily) (Striant) • implanted pellets (the oldest form of testosterone replacement, first used in 1938 and now rarely used).
Oral testosterone replacement is not recommended because of very high first-pass metabolism of testosterone in the liver. Long-acting (10-12 weekly) testosterone injection or daily application of a transdermal testosterone gel is acceptable to most men.
CONCLUSION
A low testosterone level found in a sample taken at 9am requires a serum prolactin, LH and FSH measurement to rule out secondary hypogonadism. Also, SHBG measurement, with a view to estimation of free testosterone, aids interpretation of the testosterone results.
Addition of these tests, while not always done, greatly helps decisions concerning management of potential hypogonadism.
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